Drug intelligence / Profile preview

omeprazole + clarithromycin + amoxicillin

Development stage
Approved
Lead developer
DAVA Pharmaceuticals
Modality
Drug Delivery Systems, Small Molecules
Administration
Oral
01

Overview

Omeprazole + clarithromycin + amoxicillin is a fixed-dose combination therapy used primarily for the eradication of Helicobacter pylori (H. pylori) infection and the treatment and prevention of duodenal or gastric ulcers associated with H. pylori. Omeprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, while amoxicillin is an aminopenicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. The combination works synergistically to both suppress stomach acid (improving ulcer healing and antibiotic efficacy) and eradicate H. pylori infection[1][2][3][4][5][6].

Brand names
Omeclamox-Pak
Other names
omeprazole-amoxicillin-clarithromycinamoxicillin-clarithromycin-omeprazoleamoxycillin + omeprazole + clarithromycin
02

Targets

PBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunitATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on omeprazole + clarithromycin + amoxicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omeprazole + clarithromycin + amoxicillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call